Skip to main content
. 2021 Apr 12;10(1):349–360. doi: 10.1007/s40120-021-00242-7

Fig. 1.

Fig. 1

Persistence to DRF in the overall study population (N = 160). Dashed lines represent 95% confidence intervals. The Kaplan–Meier-estimated proportion of patients remaining persistent on DRF therapy at 8 months was 88.6% (95% CI 82.5–92.7). DRF Diroximel fumarate